T3D Therapeutics’ mission, as a pharmaceutical R&D company, is to develop and commercialize T3D-959, potentially an optimal disease remedial therapeutic for the treatment of Alzheimer’s Disease. Unlike single dimension therapies in development that target one abnormality (i.e. pathology), for example beta amyloid plaques or tau bundles, this oral once-a-day therapy acts in a multidimensional manner. As a dual nuclear receptor agonist, T3D-959 may regulate a myriad of genes involved in Alzheimer’s disease pathologies and thus may offer a greater potential to slow, stop or reverse disease progression.